News, publications
& more

05/26/2023

OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment

05/25/2023

OncoHost to Present PROphet® Biomarker Model that Accurately Predicts Clinical Benefit to ICI-Based Treatment at ASCO 2023

05/25/2023

PROphet Biomarker Model Results to be Presented

05/04/2023

Other news to note for May 4, 2023

05/04/2023

OncoHost Licenses Biosensing Technology From BGN Technologies to Predict Immunotherapy Response

04/21/2023

The Impact of Proteomics on Precision Oncology

03/31/2023

Is ChatGPT Fast Becoming ChatMD? Introducing Generative AI To Healthcare

02/23/2023

Latest News: OncoHost announced official launch of PROphet non-small cell lung cancer (NSCLC) Test in the United States.

02/22/2023

AI/ML Enables Earlier Cancer Detection, Guided Treatment

02/20/2023

Health IT Product News Report February 2023

02/09/2023

Health IT Business News – February 9, 2023

02/09/2023

OncoHost lunches non-small cell lung cancer test in U.S.

02/04/2023

Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine

02/02/2023

Israel is starting to win the battle with cancer

02/02/2023

Blood Test Offers Hope For Lung Cancer Patients

02/01/2023

OncoHost Launches PROphet NSCLC Cancer Test in the United States

02/01/2023

OncoHost Launches PROphet® NSCLC Test in the United States; Predictive Blood Test Guides First-Line Treatment Decisions for Advanced Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients

02/01/2023

OncoHost Launches NSCLC Test in the U.S.

02/01/2023

OncoHost Launches PROphet® NSCLC Test in the United States

01/24/2023

Oncohost partners with US research institutions to analyze resistance mechanisms in cancer

01/12/2023

OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform

01/12/2023

Health IT Business News – January 12, 2023

01/10/2023

Texas Research Institute, TGen, OncoHost Partner to ID Lung Cancer Resistance Mechanisms

01/10/2023

New Study Combines AI And Multiomics Analysis To Understand Cancer Resistance Mechanisms

01/09/2023

Pharma – 2023 Health IT Predictions

12/14/2022

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023

12/02/2022

Health Tech World Awards: Recognising the most impactful startups

11/17/2022

Health IT Business News – November 17, 2022

11/11/2022

OncoHost to present proteomics-based biomarker model for clinical benefit to immunotherapy in NSCLC patients at SITC 2022

10/05/2022

Health IT Hires, Appointments, and Who’s Hiring

10/03/2022

Appointments and advancements for Oct. 3, 2022

10/03/2022

OncoHost: Chris Dingman, James Whelan

10/03/2022

OncoHost preparing launch of proteomics diagnostics platform for cancer, immunotherapy

09/06/2022

“Be human” – Founders reveal how to secure “real” investment for your startup

09/05/2022

Novel Diagnostic Platform Predicts NSCLC Patient Response to Immunotherapy

08/29/2022

Proteins provide clue to predict cancer treatment outcome

07/27/2022

Singapore delegation meets Israeli startups in Tel Aviv

07/22/2022

Surveys and Reports Roundup

07/14/2022

Florida Cancer Specialists & Research Institute Participating in Global Clinical Trial Analyzing Patient Responsiveness to Immunotherapy Treatment

06/30/2022

NGS Solution Detects Aneuploidies, AI-Powered Biomarker Test for Urothelial Cancer

06/27/2022

SomaLogic Partners with OncoHost for Precision Cancer Diagnostics

06/27/2022

New Directions: What Innovations Are Coming Down the Pike for Lung Cancer?

06/23/2022

Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

06/22/2022

DeciBio’s Peripheral Biomarkers Q&A with Dr. Ofer Sharon of OncoHost

06/21/2022

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients

06/17/2022

SomaLogic, OncoHost announce license agreement for the development of precision cancer diagnostics

06/16/2022

Health IT Business News – June 16, 2022

06/14/2022

SomaLogic, OncoHost sign agreement to develop precision cancer therapy

06/14/2022

SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics

06/13/2022

OncoHost Licenses SomaLogic Platform to Develop Tests to Predict Patient Response to Immunotherapies

06/13/2022

SomaLogic, OncoHost ink agreement to develop tests

06/13/2022

SomaLogic in licensing deal with OncoHost

06/13/2022

SomaLogic inks license deal with OncoHost to develop precision cancer diagnostics

05/16/2022

Digital health news, funding roundup in the prior week; May 16, 2022

05/13/2022

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology

05/13/2022

AI-Powered oncology platform raises $35 million Series C funding round

05/12/2022

Global Roundup: Medtronic Kicks Off Aortic Stenosis Study in Japan

05/12/2022

OncoHost nabs $35M in funding round

05/11/2022

FORTUNE Term Sheet Newsletter

05/11/2022

Personalized cancer therapy co OncoHost raises $35m

05/11/2022

OncoHost Raises $35M For Precision Oncology Diagnostic Solution

05/10/2022

Oncohost’s $35M series C predicts expansion of Prophet study

05/10/2022

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology

05/10/2022

Can OncoHost’s PROphet predict host response to cancer treatments? Investors are waiting to find out

05/10/2022

OncoHost Raises $35M in Series C Funding

05/10/2022

$35 Million In New Funding For AI To Personalize Cancer Treatment

05/10/2022

OncoHost Raises $35M in Series C Financing

05/10/2022

OncoHost Raises $35M in Series C Financing

05/10/2022

OncoHost Raises $35M for AI-Powered Precision Oncology Platform

05/10/2022

Osmind raises $40M for emerging mental health treatment EHR and more digital health fundings

05/10/2022

Israeli biotech startup OncoHost raises $35 million in funding to personalize cancer treatment using AI

05/09/2022

Israeli startups eye growing precision oncology market

05/05/2022

‘Bio’ food, precision oncology to take center stage at biomed summit in Tel Aviv

04/08/2022

PROPHETIC Study of Immunotherapy Diagnostic Adds New Site in Buffalo, NY

04/08/2022

In Brief This Week: Qiagen, Renalytix, OpGen, PerkinElmer, Avacta, Paige, More

04/06/2022

OncoHost enters trial partnership to evaluate resistance to immunotherapy

04/05/2022

OncoHost Announces AI-Based Clinical Trial Collaboration to Analyze Immunotherapy Resistance

03/23/2022

Nobel laureate Prof. Aaron Ciechanover to discuss advances in precision medicine

03/16/2022

Driving Progress in Personalized Cancer Therapy

03/14/2022

Lifting the veil of uncertainty around cancer treatments

03/02/2022

Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space

03/01/2022

Oncology Peer Review On-The-Go: Ofer Sharon, MD, Discusses OncoHost and PROPHETIC Trial for NSCLC

02/03/2022

3 Researchers Developing Innovative Strategies In Cancer Therapy

01/28/2022

2022 Predictions for AI and Machine Learning in Healthcare

01/24/2022

Next Israeli astronaut’s 35 experiments revealed

01/24/2022

Space meat and hummus: Israel finalizes experiments for upcoming ISS mission

01/17/2022

OncoHost Announces Interim Results From PROPHETIC Trial, Multicenter Assessment Of NSCLC Patient Response To Immunotherapy

12/20/2021

OncoHost Collaborates with Lung Biobank Heidelberg to Discover Lung Cancer Biomarkers

12/17/2021

Israeli research institute makes great contributions to cancer research

12/16/2021

Global Roundup: Aussie Biopharma Raises $25 Million to Expand in US

12/13/2021

OncoHost, Heidelberg University Hospital Strike Lung Cancer Biomarker Alliance

12/07/2021

Health IT Appointments and Hires

12/01/2021

OncoHost: David Gandara

11/15/2021

Dr. Ofer Sharon, CEO of OncoHost, Talks the Potential Impact of Precision Medicine on Cancer Therapy

11/01/2021

CTech’s 20 Minute Leaders Podcast Interview with Ofer Sharon, CEO of OncoHost

10/31/2021

OncoHost’s Algorithms Predict Cancer Patients Response To Treatments

09/20/2021

Oncohost platform predicts response to lung cancer therapy

08/20/2021

OncoHost Wins Frost & Sullivan 2021 Technology Innovation Leadership Award for Excellence in Best Practices

08/19/2021

Global Roundup: Sweden’s Cellink Rebrands as BICO and Other News

07/06/2021

OncoHost’s Focus on the Patient Offers Precision Oncology to Combat Cancer

06/22/2021

Oncohost opens trial sites for study evaluating its AI proteomics profiling technology

06/17/2021

Israel’s OncoHost, UK’s NHS to study cancer patient responses to immunotherapies

06/16/2021

NHS opens 8 clinical trial sites to assess cancer treatment

06/16/2021

NHS Opens Eight UK Clinical Trial Sites to Assess Cancer Patient Response to Immunotherapy in Collaboration with OncoHost

06/16/2021

NHS opens eight UK clinical trial sites to assess cancer patient response to immunotherapy in collaboration with OncoHost

06/14/2021

The Impact of Technology on Healthcare

05/21/2021

Which Israeli technologies will soon be going to space?

03/30/2021

How an AI tool predicts responses to cancer treatment

02/17/2021

Dr. Ofer Sharon, CEO of OncoHost, Discusses Technology to Improve Cancer Care

02/01/2021

January 2021 smiles upon Israeli startups: 4 new Unicorns and over $1B in funding

01/26/2021

Health IT Appointments and Hires

01/22/2021

OncoHost Secures $8 Million Series B Funding Round

01/22/2021

Oncohost nabs $8M series B round for AI-powered precision oncology platform

01/21/2021

OurCrowd leads $8M Series B in Israeli personalized cancer therapy startup

01/21/2021

Money on the Move: January 15-20

01/20/2021

The evolution of machine learning in oncology: an interview with Dr Ofer Sharon

01/20/2021

OncoHost Secures $8M in Series B Funding

01/19/2021

OncoHost raises $8 million to develop AI that predicts cancer treatment responses

01/19/2021

Israel-based OncoHost closes $8M in Series B funding to provide personalized cancer therapy for more effective treatment

01/19/2021

Israeli Startup OncoHost Raises $8M For AI Precision Oncology Platform

01/12/2021

Nobel prizewinner Ciechanover hails ‘much more precise’ cancer treatment

12/31/2020

OncoHost – Personalized cancer therapy for more effective treatment

12/08/2020

Dr. Ofer Sharon, CEO of OncoHost – Interview Series

11/15/2020

OncoHost Offers New Hope For Cancer Sufferers

11/12/2020

Israeli blood test offers better choices to fight cancer

11/04/2020

Oncohost platform improves immunotherapy response predictions

10/06/2020

OncoHost Data on Host Immunotherapy Response to be Presented This Week

08/07/2020

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients?

06/04/2020

PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients

06/04/2020

PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients

04/07/2020

Developing Personalized Strategies To Maximize Cancer Therapy Success

03/01/2020

Personalized Cancer Treatment, A Real Possibility?

02/23/2020

$8m in BIRD grants go to Israeli-US collaborations in agtech and health

02/18/2020

Backed by EU funds, Israeli researcher tackles treatment-resistant cancer

02/10/2020

Startup develops blood test that aims to undermine tumors’ resilience

02/05/2020

Top 5 Recent Advances In Israeli Cancer Research And Treatment

02/04/2020

Cancer Treatment Doesn’t Work on Everyone. One Israeli Doctor Explains Why.

01/26/2020

US-Israel Foundation To Invest $8M In 9 New Joint Initiatives

01/21/2020

OncoHost, RayBiotech Awarded $1 Million Grant for Precision Oncology

01/21/2020

OncoHost, RayBiotech Win $1M From BIRD Foundation

01/21/2020

OncoHost, RayBiotech Win $1M From BIRD Foundation

01/15/2020

New Israeli Tech Can Determine Specific Cancer Treatment for Patients

12/31/2019

Israeli algorithm may predict if cancer patients will respond to treatment

12/17/2019

Israeli Firm OncoHost Using Host Response Proteomics to Inform Cancer Therapy

12/08/2019

First-Of-Its-Kind Lab To Improve Personalized Cancer Therapy Opens In Israel

12/05/2019

Hillel’s Tech Corner: Cancer treatment personalized

05/27/2023

OncoHost to Present PROphet® Biomarker Model that Accurately Predicts Clinical Benefit to ICI-Based Treatment at ASCO 2023

05/04/2023

OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech

02/01/2023

OncoHost Launches PROphet® NSCLC Test in the United States

01/11/2023

OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform

01/10/2023

Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer

11/07/2022

OncoHost to Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022

10/03/2022

OncoHost Announces New Executive Appointments Ahead of Imminent Launch of its Precision Oncology Platform

06/21/2022

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients

06/13/2022

SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics

05/10/2022

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology

04/05/2022

OncoHost Announces Clinical Trial Collaboration with Roswell Park Comprehensive Cancer Center to Analyze Immunotherapy Resistance

02/14/2022

OncoHost CEO to Present at 2022 BIO CEO & Investor Conference

01/12/2022

OncoHost Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

12/13/2021

OncoHost Announces Collaboration with Heidelberg University’s Lung Research Biobank to Discover Lung Cancer Biomarkers

11/30/2021

OncoHost Welcomes UC Davis Professor, David Gandara, M.D., to Scientific Advisory Board

11/12/2021

OncoHost to Present Data at SITC 2021 on Predicting NSCLC Patient Response to Immunotherapy Utilizing Proteomic Profiling

09/13/2021

OncoHost Publishes Data Identifying Predictive Signature for Response to Immunotherapy in Lung Cancer Patients

08/18/2021

OncoHost Wins Frost & Sullivan 2021 Technology Innovation Leadership Award for Excellence in Best Practices

06/16/2021

NHS Opens Eight UK Clinical Trial Sites to Assess Cancer Patient Response to Immunotherapy in Collaboration with OncoHost

01/19/2021

OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform

01/11/2021

OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board

11/09/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020

10/05/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO

09/17/2020

OncoHost to Present Data on Host Response Profiling for NSCLC Patients at ESMO Virtual Congress 2020

03/14/2020

OncoHost to Present Data on Host Response Profiling for Melanoma Patients at 2020 ASCO Annual Meeting

01/21/2020

BIRD – Israel-U.S. Binational Industrial R&D Foundation to Invest $8 million in 9 New Projects

01/21/2020

OncoHost and RayBiotech Awarded $1 Million Grant From the BIRD Foundation to Advance Precision Oncology for Patients Receiving Immunotherapy

12/04/2019

OncoHost Opens First-of-its-Kind Proteomics Laboratory for Host Response Analysis for Cancer Therapy

10/31/2019

OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
27518
T. (855) 950-2112
E. contact@oncohost.com

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
3057324
T. +972 485 37558
E. contact@oncohost.com

Please Note:
PROphet® NSCLC is currently available in all US states except NY